BF
RPRX icon

BOK Financial’s Royalty Pharma RPRX Stock Holding History

BOK Financial’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-18,311
Closed -$483K – 1483
2024
Q2 		$483K Buy
18,311
+31
+0.2% +$859 0.01% 615
2024
Q1 		$547K Buy
18,280
+2,844
+18% +$83.8K 0.01% 566
2023
Q4 		$434K Sell
15,436
-2,266
-13% -$62.3K 0.01% 571
2023
Q3 		$476K Buy
17,702
+12,700
+254% +$377K 0.01% 545
2023
Q2 		$154K Hold
5,002
– – ﹤0.01% 666
2023
Q1 		$180K Buy
+5,002
New +$185K ﹤0.01% 680
2022
Q4 		– Sell
-5,002
Closed -$201K – 933
2022
Q3 		$201K Hold
5,002
– – ﹤0.01% 847
2022
Q2 		$210K Buy
+5,002
New +$205K ﹤0.01% 856
2022
Q1 		– Sell
-7,710
Closed -$307K – 1014
2021
Q4 		$307K Buy
+7,710
New +$300K ﹤0.01% 819

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BOK Financial's RPRX Position: Q3 2024 in Review

BOK Financial sold out of Royalty Pharma (RPRX) in Q3 2024, closing a stake of 18,311 shares — an estimated $483K sold.

BOK Financial first reported a position in RPRX in Q4 2021 and held it in 9 quarters. The position peaked at $547K in Q1 2024. 395 funds tracked by Wall St. Rank hold RPRX as of Q3 2024.

  • BOK Financial reported no remaining Royalty Pharma position as of Q3 2024 after selling out during the quarter.
  • BOK Financial sold 18,311 Royalty Pharma shares in Q3 2024, an estimated $483K.
  • BOK Financial first reported a position in Royalty Pharma in Q4 2021 and held it in 9 quarters.
  • BOK Financial's Royalty Pharma position peaked at $547K in Q1 2024.
  • 395 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2024.

Based on BOK Financial's 13F filing for Q3 2024, filed 14 Nov 2024.